newsfilter
← Latest News
Business Wire·

Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress

Tab-cel® U.S. BLA On-Track With PDUFA Target Action Date of January 15, 2025 First Patient Dosed for ATA3219 Non-Hodgkin's Lymphoma Study; Initial Clinical Data Expected Q1 2025 ATA3219 Lupus Nephritis and